Mayelana-umdlavuza / ukwelashwa / ukuhlolwa kwezilingo / izifo / i-soft-tissue-sarcoma / ukwelashwa

Ukwelashwa Kwezilingo Zomtholampilo Wezicubu Ezithambile Sarcoma

Ukuhlolwa kwemitholampilo kuyizifundo zocwaningo ezibandakanya abantu. Ukuhlolwa kwemitholampilo kulolu hlu kungokwelashwa kwezicubu ezithambile ze-sarcoma. Zonke izilingo ohlwini zisekelwa yi-NCI.

Imininingwane eyisisekelo ye-NCI mayelana nokuhlolwa komtholampilo ichaza izinhlobo nezigaba zezilingo nokuthi zenziwa kanjani. Ukuhlolwa komtholampilo kubheka izindlela ezintsha zokuvimbela, ukuthola, noma ukwelapha izifo. Ungahle uthande ukucabanga ngokubamba iqhaza esivivinyweni somtholampilo. Khuluma nodokotela wakho ngosizo lokunquma ukuthi ngabe kukulungele yini.

I-Erdafitinib ekwelapheni iziguli ezinamaqhubu aqinile abuyiselwe emuva noma abhekele emuva, i-Non-Hodgkin Lymphoma, noma ukuphazamiseka kwe-Histiocytic nge-FGFR Mutations (Isilingo Sokwelashwa KWEZINGANE ZABANTWANA)

Lesi sigaba sesibili sesivivinyo se-Pediatric MATCH sicwaninga ukuthi i-erdafitinib isebenza kanjani ekwelapheni iziguli ezinamathumba aqinile, i-non-Hodgkin lymphoma, noma ukuphazamiseka kwe-histiocytic okusabalalele kwezinye izindawo emzimbeni futhi kubuyile noma kungaphenduli ekwelashweni ngezinguquko ze-FGFR. I-Erdafitinib ingamisa ukukhula kwamangqamuzana omdlavuza ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: izindawo eziyi-107

I-Tazemetostat Ekwelapheni Iziguli Ezinamaqhubu Aqinile Aphindwayo noma Aphikisayo Aphindayo noma Aphikisayo, i-Non-Hodgkin Lymphoma, noma i-Histiocytic Disorders ene-EZH2, i-SMARCB1, noma i-SMARCA4 Gene Mutations (Isilingo Sokwelashwa KWEZINGANE ZABANTWANA)

Lesi sigaba sesibili sesivivinyo se-Pediatric MATCH sicwaninga ukuthi i-tazemetostat isebenza kanjani ekwelapheni iziguli ezinamathumba aqinile, i-non-hodgkin lymphoma, noma ukuphazamiseka kwe-histiocytic okusabalalele kwezinye izindawo emzimbeni futhi kubuyile noma kungaphenduli ekwelashweni futhi kune-EZH2, SMARCB1 , noma ukuguqulwa kwezakhi zofuzo ze-SMARCA4. I-Tazemetostat ingamisa ukukhula kwamangqamuzana wesimila ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: Izindawo eziyi-109

I-PI3K / mTOR Inhibitor LY3023414 ekwelapheni iziguli ezinamaThumba aQinisekile aQinisekile abuyiselwe emuva noma aphikisayo, i-Non-Hodgkin Lymphoma, noma ukuphazamiseka kwe-Histiocytic nge-TSC noma i-PI3K / MTOR Mutations (Isilingo Sokwelashwa KWEZINGANE ZABANTWANA)

Lesi sigaba sesibili sesivivinyo se-Pediatric MATCH sicwaninga ukuthi iPI3K / mTOR inhibitor LY3023414 isebenza kanjani ekwelapheni iziguli ezinamathumba aqinile, i-non-Hodgkin lymphoma, noma ukuphazamiseka kwe-histiocytic nge-TSC noma i-PI3K / MTOR izinguquko ezisabalalele kwezinye izindawo emzimbeni (metastatic) kanye abuyile (aphindaphindiwe) noma awaphenduli ekwelashweni (ukuphikisa). I-PI3K / mTOR inhibitor i-LY3023414 ingamisa ukukhula kwamangqamuzana omdlavuza ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: izindawo eziyi-107

I-Palbociclib ekwelapheni iziguli ezinama-Tumors Aqinile Aphindekile noma Aphikisayo i-Rb Positive Advanced Solid Tumors, i-Non-Hodgkin Lymphoma, noma i-Histiocytic Disorders Ngokusebenzisa Ukuguqulwa Kwama-Cell Cycle Genes (Isivivinyo Sokwelashwa KWE-MATCH)

Lesi sigaba sesibili sesivivinyo se-Pediatric MATCH sicwaninga ukuthi i-palbociclib isebenza kanjani ekwelapheni iziguli ezinezicubu eziqinile ze-Rb, i-non-Hodgkin lymphoma, noma ukuphazamiseka kwe-histiocytic ngokwenza kusebenze ushintsho (ukuguquka) kwezakhi zofuzo zomjikelezo weseli ezisabalalele kwezinye izindawo emzimbeni futhi sezifikile emuva noma ungaphenduli ekwelashweni. IPalbociclib ingamisa ukukhula kwamangqamuzana omdlavuza ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: izindawo ezingu-97

I-Larotrectinib ekwelapheni iziguli ezinamaqhubu aqinile abuyiselwe emuva noma abhekele emuva, i-non-Hodgkin Lymphoma, noma ukuphazamiseka kwe-Histiocytic nge-NTRK Fusions (Isilingo Sokwelashwa KWE-MATCH)

Lesi sigaba sesibili sesivivinyo se-Pediatric MATCH sicwaninga ukuthi i-larotrectinib isebenza kahle kanjani ekwelapheni iziguli ezinamathumba aqinile, i-non-Hodgkin lymphoma, noma izifo ze-histiocytic ezine-NTRK fusions ezisabalalele kwezinye izindawo emzimbeni futhi zibuya noma aziphenduli ekwelashweni. I-Larotrectinib ingamisa ukukhula kwamangqamuzana omdlavuza ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: Izindawo eziyi-109

I-Cabozantinib-S-Malate Ekwelapheni Iziguli Ezincane NgeSurcomas Ephindaphindayo, Ekhanyayo, noma Esanda Ukutholakala, iWilms Tumor, noma Amanye Amathumba Angajwayelekile

Lesi sigaba sesivivinyo sesi-II sihlola ukuthi isebenza kanjani kahle i-cabozantinib-s-malate ekwelapheni iziguli ezisencane ezinama-sarcomas, isimila se-Wilms, noma ezinye izicubu ezingavamile ezibuyile, ezingaphenduli ekwelashweni, noma ezisanda kutholakala. I-Cabozantinib-s-malate ingamisa ukukhula kwamangqamuzana e-tumor ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwesimila nokukhula kwesigaxa segazi.

Indawo: izindawo eziyi-137

I-Olaparib ekwelapheni iziguli ezinamaqhubu aqinile abuyisiwe abuye abuyele emuva noma aphikisayo, i-non-Hodgkin Lymphoma, noma ukuphazamiseka kwe-Histiocytic enamaphutha ekulungisweni kokulimala kwe-DNA (Isilingo Sokwelashwa KWE-MATCH)

Lesi sigaba sesibili sesivivinyo se-Pediatric MATCH sicwaninga ukuthi i-olaparib isebenza kanjani ekwelapheni iziguli ezinamathumba aqinile, i-non-Hodgkin lymphoma, noma ukuphazamiseka kwe-histiocytic okunokukhubazeka ku-deoxyribonucleic acid (DNA) yokulungisa izakhi zofuzo ezisabalalele kwezinye izindawo emzimbeni (okuthuthukile) kanye ubuyile (ubuyele emuva) noma ungaphenduli ekwelashweni (ukuphikisa). I-Olaparib ingamisa ukukhula kwamangqamuzana wesimila ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: izindawo eziyi-105

I-Vemurafenib ekwelapheni iziguli ezinamaqhubu aqinile abuyiselwe emuva noma aphikisayo, i-non-Hodgkin Lymphoma, noma ukuphazamiseka kwe-Histiocytic nge-BRAF V600 Mutations (Isilingo Sokwelashwa KWEZINGANE ZABANTWANA)

Lesi sigaba sesibili sesivivinyo se-Pediatric MATCH sihlola ukuthi i-vemurafenib isebenza kanjani ekwelapheni iziguli ezinamathumba aqinile, i-non-Hodgkin lymphoma, noma ukuphazamiseka kwe-histiocytic ngokushintshwa kwe-BRAF V600 okusabalalele kwezinye izindawo emzimbeni futhi kubuyile noma kungaphenduli ekwelashweni. IVemurafenib ingamisa ukukhula kwamangqamuzana wesimila ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: Izindawo eziyi-106

I-Atezolizumab ekwelapheni iziguli ezinesifo esisanda kutholakala kanye nesifo se-metastatic Alveolar Soft Part Sarcoma esingeke sisuswe ngokuhlinzwa

Lesi sigaba sesivivinyo sesi-II sihlola ukuthi i-atezolizumab isebenza kanjani ekwelapheni iziguli ezine-alveolar soft part sarcoma engakalashwa, isabalale ukusuka lapho iqale khona yafika kwezinye izindawo emzimbeni futhi ayinakususwa ngokuhlinzwa. I-Immunotherapy enama-antibody monoclonal, njenge-atezolizumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa amandla amangqamuzana e-tumor ukuthi akhule futhi asabalale.

Indawo: izindawo ezingama-39

I-Nivolumab ne-Ipilimumab ekwelapheni iziguli ezine-HIV ezihlobene nokubuyela emuva noma ukubuyisela emuva i-Classical Hodgkin Lymphoma noma ama-Tumors aqinile aMetastatic noma awanakususwa ngokuhlinzwa

Lesi sigaba sokuhlolwa kwesigaba sokuqala sihlola imiphumela emibi kanye nomthamo omuhle kakhulu we-nivolumab lapho unikezwa nge-ipilimumab ekwelapheni iziguli ezine-human immunodeficiency virus (HIV) ezihambisana ne-classical Hodgkin lymphoma ebuyile ngemuva kwesikhathi sokwenza ngcono noma engaphenduli ekwelashweni, noma izicubu eziqinile zisakazekele kwezinye izindawo emzimbeni noma azikwazi ukususwa ngokuhlinzwa. I-Immunotherapy enama-antibody monoclonal, njenge-ipilimumab ne-nivolumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa ikhono lamangqamuzana e-tumor ukukhula nokukhula. I-Ipilimumab i-antibody esebenza ngokumelene ne-molecule ebizwa nge-cytotoxic T-lymphocyte antigen 4 (CTLA-4). I-CTLA-4 ilawula ingxenye yamasosha akho omzimba ngokuyivala. I-Nivolumab uhlobo lwe-antibody ecaciselwe ukufa komuntu okuhleliwe 1 (PD-1), iphrotheni elibhekene nokucekelwa phansi kwamaseli omzimba. Ukunikeza i-ipilimumab nge-nivolumab kungasebenza kangcono ekwelapheni iziguli ezine-HIV ezihambisana ne-classical Hodgkin lymphoma noma izicubu eziqinile uma kuqhathaniswa ne-ipilimumab ene-nivolumab iyodwa.

Indawo: izindawo ezingama-28

I-MDM2 Inhibitor AMG-232 kanye ne-Radiation Therapy Ekwelapheni Iziguli ezine-Soft Tissue Sarcoma

Lesi sigaba sokuhlolwa kwe-Ib sicwaninga ngemiphumela emibi ye-MDM2 inhibitor AMG-232 kanye nokwelashwa ngemisebe ekwelapheni iziguli ezinezicubu zomzimba ezithambile. I-MDM2 inhibitor i-AMG-232 ingamisa ukukhula kwamangqamuzana omdlavuza ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli. Ukunikeza i-MDM2 inhibitor i-AMG-232 kanye nokwelashwa ngemisebe ngaphambi kokuhlinzwa kungenza isimila sibe sincane futhi kunciphise inani lezicubu ezijwayelekile ezidinga ukususwa.

Indawo: izindawo ezingama-27

INivolumab enayo noma engenayo i-Ipilimumab ekwelapheni iziguli ezisencane ezinezicubu eziqinile eziphindayo noma eziphikisayo noma iSarcomas

Lesi sigaba sesivivinyo se-I / II sihlola imiphumela emibi kanye nomthamo omuhle kakhulu we-nivolumab lapho unikezwa nge-ipilimumab noma ngaphandle kwayo ukuze ubone ukuthi basebenza kahle kanjani ekwelapheni iziguli ezincane ezinamathumba aqinile noma ama-sarcomas abuyile (aphindaphindiwe) noma awaphenduli ekwelashweni ( okuchasayo). I-Immunotherapy enama-antibody monoclonal, njenge-nivolumab ne-ipilimumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa ikhono lamangqamuzana e-tumor ukukhula nokukhula. Akukaziwa ukuthi ngabe i-nivolumab isebenza kangcono iyodwa noma ine-ipilimumab ekwelapheni iziguli ezinamathumba aqinile aphindayo noma aphikisayo noma ama-sarcomas.

Indawo: izindawo ezingama-24

Selinexor ku-Advanced Liposarcoma

Lokhu ukucwaninga okungahleliwe, okuhlukahlukene, okungaboni kabili, okulawulwa nge-placebo, Isigaba 2-3 sifundo seziguli ezitholwe zine-liposarcoma engaphenduki engaphenduki. Cishe iziguli ezingama-279 zizokwenziwa ngezikhathi ezithile ukutadisha ukwelashwa (i-selinexor noma i-placebo).

Indawo: izindawo ezingama-21

(VOYAGER) Ucwaningo lwe-Avapritinib vs Regorafenib ezigulini ezine-GIST Yendawo Engathuthukisiwe Engaphenduki noma YeMetastatic

Lesi yilebuli evulekile, engahleliwe, yokufunda kweSigaba 3 ezigulini ezine-GIST (i-GIST esezingeni eliphakeme) yasendaweni ye-avapritinib (eyaziwa nangokuthi yi-BLU-285) uma iqhathaniswa ne-regorafenib ezigulini ezake zaphathwa nge-imatinib kanye ne-1 noma enye i-2 TKIs.

Indawo: izindawo eziyi-14

Ucwaningo Lwesigaba 1 se-EZH2 Inhibitor Tazemetostat Ezifundweni Zengane ezine-INI1-Negative Tumors noma i-Synovial Sarcoma ebuyile noma ephikisayo.

Lesi yisigaba I, ilebula evulekile, ukukhuphuka kwedosi kanye nocwaningo lokukhulisa umthamo ngomthamo womlomo we-BID we-tazemetostat. Izihloko zizohlolwa ukufaneleka ngaphambi kwezinsuku eziyi-14 zomthamo wokuqala ohleliwe we-tazemetostat. Umjikelezo wokwelashwa uzoba izinsuku ezingama-28. Ukuhlolwa kwempendulo kuzohlolwa ngemuva kwamasonto ayisi-8 ekwelashwa bese kuthi njalo emavikini ayisishiyagalombili ngenkathi kufundwa. Ucwaningo lunezingxenye ezimbili: Ukukhuphuka Kwedosi kanye Nokwandiswa Kwedosi. Ukukhuphuka komthamo wezihloko ngalezi zilonda ezimbi ezibuyile / eziphikisayo ezilandelayo: - Izicubu zeRhabdoid: - Isigaxa se-rhabdoid esine-Atypical teratoid (ATRT) - Isigaxa esibi se-rhabdoid (MRT) - Isigaxa seRhabdoid sezinso (RTK) - Izicubu ezikhethiwe ezinezici ze-rhabdoid - i-INI1-negative tumors :

Indawo: izindawo eziyi-14

I-Adavosertib ne-Irinotecan Hydrochloride Ekwelapheni Iziguli Ezincane Ngezicubu Eziqinile Eziphindayo noma Eziphikisayo

Lesi sigaba sesivivinyo se-I / II sihlola imiphumela emibi kanye nomthamo omuhle we-adavosertib ne-irinotecan hydrochloride ekwelapheni iziguli ezisencane ezinamathumba aqinile abuyile (abuyele emuva) noma angaphendulanga ekwelashweni okujwayelekile (okwenqabayo). I-Adavosertib ne-irinotecan hydrochloride kungamisa ukukhula kwamangqamuzana wesimila ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: izindawo ezingama-22

Isivivinyo Sesigaba Sesithathu se-Anlotinib eMetastatic noma Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma kanye neSynovial Sarcoma

Lolu cwaningo luhlola ukuphepha nokusebenza kwe-AL3818 (anlotinib) hydrochloride ekwelapheni i-metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), ne-synovial sarcoma (SS). Bonke ababambiqhaza abane-ASPS bazothola ilebula evulekile i-AL3818. Kubahlanganyeli abane-LMS noma i-SS, i-AL3818 izofaniswa ne-IV dacarbazine. Ababili kwabathathu babahlanganyeli bazothola i-AL3818, ingxenye eyodwa kwezintathu yabahlanganyeli izothola i-IV dacarbazine.

Indawo: izindawo eziyi-14

I-Nab-Paclitaxel ne-Gemcitabine Hydrochloride ekwelapheni Intsha noma Abadala Abancane nge-Recurrent or Refractory Osteosarcoma, i-Ewing Sarcoma, iRhabdomyosarcoma, noma iSoft Tissue Sarcoma

Lesi sigaba sesivivinyo sesi-II sihlola ukuthi i-nab-paclitaxel ne-gemcitabine hydrochloride isebenza kanjani ekwelapheni intsha noma abantu abadala abane-osteosarcoma, i-Ewing sarcoma, i-rhabdomyosarcoma, noma i-sarcoma ethambile yezicubu ebuyile noma engaphenduli ekwelashweni. Izidakamizwa ezisetshenziselwa ukwelashwa ngamakhemikhali, njenge-nab-paclitaxel ne-gemcitabine hydrochloride, zisebenza ngezindlela ezehlukene ukunqanda ukukhula kwamangqamuzana ezinhlungu, kungaba ngokubulala amaseli, ngokuwavimba ekuhlukaniseni, noma ngokuwavimba ekusakazeni.

Indawo: izindawo eziyi-18

I-Olaparib neTemozolomide ekwelapheni iziguli ezine-Uterine Leiomyosarcoma esezingeni eliphakeme, noma engabonakali

Lesi sigaba sesibili sokuhlolwa kwesilingo i-olaparib ne-temozolomide ekwelapheni iziguli ezine-uterine leiomyosarcoma (LMS) esisabalalele kwezinye izindawo emzimbeni (ezithuthukile noma zemetastatic) noma ezingenakususwa ngokuhlinzwa (okunganqandeki). I-Olaparib ingamisa ukukhula kwamangqamuzana wesimila ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli. Izidakamizwa ezisetshenziselwa ukwelashwa ngamakhemikhali, njenge-temozolomide, zisebenza ngezindlela ezehlukene ukunqanda ukukhula kwamangqamuzana ezinhlungu, kungaba ngokubulala amaseli, ngokuwavimba ekuhlukaniseni, noma ngokuwavimba ekusakazeni. Ukunikeza i-olaparib ne-temozolomide kungasebenza kangcono kunokunikeza noma imuphi umuthi owodwa ekwelapheni iziguli ezine-LMS.

Indawo: izindawo eziyi-12

Ukuphepha, Ukubekezelela kanye ne-PK Study yeDCC-2618 Ezigulini Ezinama-Malignancies Athuthukile

Lesi yisigaba sokukhula kwesilinganiso se-Phase 1, open-label, first-in-human (FIH) esenzelwe ukuhlola ukuphepha, ukubekezelelana, i-pharmacokinetics (PK), i-pharmacodynamics (PD) nomsebenzi wokuqala we-antitumor we-DCC-2618, owenziwa ngomlomo (PO), ezigulini zabantu abadala ezinokulimala okuthuthukile. Ucwaningo luqukethe izingxenye ezi-2, isigaba sokwanda komthamo kanye nesigaba sokunweba.

Indawo: izindawo eziyi-12

UNelfinavir Mesylate ekwelapheni iziguli ezineKaposi Sarcoma

Lesi sivivinyo sesigaba sesibili sokuhlola ukuthi i-nelfinavir mesylate isebenza kanjani ekwelapheni iziguli ezineKaposi sarcoma. I-Nelfinavir mesylate ingamisa ukukhula kwamangqamuzana e-tumor ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: izindawo eziyi-11

I-sEphB4-HSA ekwelapheni iziguli ezineKaposi Sarcoma

Lesi sigaba sesibili sokuhlolwa kwesivivinyo se-EphB4-HSA fusion protein (sEphB4-HSA) ekwelapheni iziguli ezineKaposi sarcoma. I-Recombinant EphB4-HSA fusion protein ingavimba ukukhula kwemithambo yegazi enikeza igazi umdlavuza, futhi ingavimbela namaseli womdlavuza ukuthi angakhuli.

Indawo: izindawo eziyi-10

Isigaba II, Isifundo Esinabaningi se-EZH2 Inhibitor Tazemetostat Ezifundweni Zabantu Abadala Ngama-INI1-Negative Tumors noma i-Syapsvial Synovial Sarcoma ebuyiselwe emuva / ephikisiwe.

Lesi yisigaba sesi-II, i-multicenter, ilebula evulekile, ingalo eyodwa, ukufundwa okuyizigaba ezimbili kwe-tazemetostat 800 mg BID elawulwa ngomlomo kumjikelezo wezinsuku ezingama-28 oqhubekayo. Ukuhlolwa kwezihloko ukunquma ukufaneleka kocwaningo kuzokwenziwa zingakapheli izinsuku ezingama-21 zomthamo wokuqala ohleliwe we-tazemetostat. Izifundo ezifanelekile zizobhaliswa kwesinye seziphuzo ezinhlanu ezisuselwa kuhlobo lwesimila: - Iqoqo 1 (Kuvaliwe ukubhaliswa): I-MRT, i-RTK, i-ATRT, noma izicubu ezikhethiwe ezinezici ze-rhabdoid, kufaka phakathi i-cell carcinoma encane yohlobo lwe-ovary hypercalcemic [SCCOHT], eyaziwa njenge-tumor ebulalayo ye-rhaboid ye-ovary [MRTO] - Iqoqo 2 (Kuvaliwe ukubhaliswa): I-sarcoma ehlehlisiwe noma ephikisayo ye-synovial ne-SS18-SSX ukuhlela kabusha - Iqoqo 3 (Kuvaliwe ukubhaliswa): Ezinye izicubu ezingezinhle ze-INI1 noma esinye isimila esiqinile esine-EZH2 inzuzo yokuguqulwa komsebenzi (GOF), kufaka phakathi:

Indawo: izindawo eziyi-12

I-SARC024: I-Protocol ye-Blanket Yokufunda ngomlomo i-Regorafenib ezigulini ezinama-Subcypes akhethiwe we-Sarcoma

Yize i-regorafenib ivunyelwe ukusetshenziswa ezigulini ezazine-GIST eqhubekayo yize i-imatinib kanye / noma i-sunitinib ngesisekelo sedatha yesigaba II neyesigaba III, ayizange ihlolwe ngendlela ehlelekile ezigulini ezinezinye izinhlobo ze-sarcoma. Njengoba kunikezwe umsebenzi we-sorafenib, i-sunitinib ne-pazopanib kuma-sarcomas ethambile, kanye nobufakazi bomsebenzi we-sorafenib ku-osteogenic sarcoma futhi mhlawumbe ne-Ewing / Ewing-like sarcoma, kunesandulela sokuhlola ama-SMOKIs (ama-molecule amancane omlomo we-kinase inhibitors) njenge-regorafenib ku-sarcomas ngaphandle kwe-GIST. Kuyaziwa futhi ukuthi ama-SMOKIs (ama-molecule amancane omlomo we-oral kinase inhibitors) afana ne-regorafenib, i-sorafenib, i-pazopanib, ne-sunitinib anamaphaneli agqagqene ama-kinase avinjelwe ngasikhathi sinye. Ngenkathi ingalingani,

Indawo: izindawo eziyi-10

Ukuphepha, Ukubekezela kanye ne-Pharmacokinetics ye-Anti-PD-1 Monoclonal Antibody Ezihlokweni Ezinama-Malignancies Athuthukile

Inhloso eyinhloko ukuhlola ukuphepha nokubekezeleleka kweToripalimab ezifundweni ezinokulimala okuhlukahlukene okuthuthukile kanye nokuhlola umthamo ophakanyisiwe weSigaba 2. Izinhloso zesibili yilezi: 1) ukuchaza iphrofayli ye-pharmacokinetic (PK) yeToripalimab, 2) ukuhlola umsebenzi we-antitumor weToripalimab; 3) ukunquma ukungabi namandla komzimba kweToripalimab; 4) hlola ukusinda okuphelele. Izinhloso zokuhlola uku: 3) hlola ukusetshenziswa kwe-PD-L1 nezimpawu ezingeziwe zokuhlola njengama-biomarkers angasiza ekukhetheni izifundo ezifanele zokwelashwa kwe-TAB001,

Indawo: izindawo eziyi-9